- Q2 2024 Rxsight Inc Earnings Call TranscriptAug 05, 2024$40.78 (-2.37%)Earnings
- Q1 2024 Rxsight Inc Earnings Call TranscriptMay 06, 2024$62.84 (+1.88%)Earnings
- Q4 2023 Rxsight Inc Earnings Call TranscriptFeb 28, 2024$56.39 (-2.64%)Earnings
- Rxsight Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Rxsight Inc Earnings Call TranscriptNov 09, 2023$23.8 (-4.19%)Earnings
- Q2 2023 Rxsight Inc Earnings Call TranscriptAug 07, 2023$28.84 (-4.09%)Earnings
- Rxsight Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Rxsight Inc Earnings Call TranscriptMay 09, 2023$19.25 (-0.82%)Earnings
- Rxsight Inc at Needham Healthcare Conference (Virtual) TranscriptApr 19, 2023
- Rxsight Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Q4 2022 Rxsight Inc Earnings Call TranscriptMar 06, 2023$15.69 (+12.96%)Earnings
- Rxsight Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Q3 2022 Rxsight Inc Earnings Call TranscriptNov 07, 2022$12.62 (+7.86%)Earnings
- Q2 2022 Rxsight Inc Earnings Call TranscriptAug 08, 2022$15.65 (-0.32%)Earnings
- Q1 2022 Rxsight Inc Earnings Call TranscriptMay 05, 2022$10.61 (-10.54%)Earnings
Rxsight Inc at JPMorgan Healthcare Conference Transcript
&-
Hi, everyone. Thanks for joining. I'm Lily Lozada. I'm on the Medtech research team here at JPMorgan. And I'm happy to have the Rxsight management team with us here today and I'll pass it over to CEO, Ron Kurtz, for a presentation, and then we'll do some Q&A.
Thank you, Louis, and good afternoon, everyone. In my presentation today, I plan to discuss how Rxsight is leading the cataract and lens replacement surgery into a new era. That is the era of adjustability. Before I do, of course, here's our forward looking statements. I'll begin with an overview of the cataract and lens replacement procedure, which involves removal of the natural lens and replacement of its focusing power with a plastic interocular lens or IOL. The main goal of cataract surgery is to provide a clear optical pathway for vision by removing the cloudy cataract, a second potential benefit that has become increasingly important over the past 20 years is reducing a patient's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)